Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

May 10, 2023

Study Completion Date

May 10, 2023

Conditions
Medulloblastoma, Childhood, RecurrentAtypical Teratoid/Rhabdoid TumorMedulloblastoma Recurrent
Interventions
BIOLOGICAL

Modified Measles Virus

Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor

BIOLOGICAL

Modified Measles Virus Lumbar Puncture

Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture

Trial Locations (8)

19104

Children's Hospital of Philadelphia, Philadelphia

43205

Nationwide Children's Hospital, Columbus

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

63130

Washington University in St. Louis, St Louis

84112

University of Utah, Salt Lake City

90027

Children's Hospital Los Angeles, Los Angeles

94143

University of California, San Francisco, San Francisco

98105

Seattle Children's Hospital, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

No More Kids With Cancer

UNKNOWN

collaborator

The Matthew Larson Foundation for Pediatric Brain Tumors

OTHER

collaborator

Vyriad, Inc.

INDUSTRY

collaborator

Mayo Clinic

OTHER

lead

Sabine Mueller, MD, PhD

OTHER